5. In addition, As2O3 activated p38 in a dose-dependent manner, but had no effect on JNK1/2. Treatment with a p38 inhibitor did not prevent As2O3-induced apoptosis.
INTRODUCTION
Arsenic trioxide (As2O3) has been adopted from traditional Chinese medicine and is highly effective in the treatment of patients suffering from acute promyelocytic leukaemia (APL) refractory to all-trans-retinoic acid; As2O3 has become an extremely important component in the clinical management of this leukaemia. [1] [2] [3] [4] Over the past 10 years, numerous studies have been performed to investigate the mechanisms of action of As2O3 on APL. These in vitro studies were performed using NB4 cells, 5 an APL cell line with chromosome translocation t(15;17) from a relapsed APL patient. In NB4 cells, As2O3 was shown to exert dose-dependent dual effects. At low concentrations (0.1-0.5 mol/L), As2O3 induces differentiation, whereas at high concentrations (0.5-2 mol/L) it induces apoptosis. 5 The therapeutic efficacy of As2O3 in APL patients and studies in the APL cell line NB4 have prompted an investigation of the effects of As2O3 in other cell lines and further elucidation of the mechanisms of actions in mediating these effects. Several studies have shown that As2O3 also exhibits potent growth inhibitory effects in several other cell lines of diverse malignant phenotypes, including cervical cancer, lung cancer, glioma, prostate cancer and breast cancer cells. [6] [7] [8] [9] [10] [11] Despite the well-documented clinical efficacy of arsenic in leukaemia therapy, the precise mechanisms of regulating the arsenic-dependent induction of apoptosis on neoplastic cells have not been elucidated.
Mitogen-activated protein kinases are a family of widely expressed serine-threonine kinases regulating important cellular processes. In mammals, three major MAPK family subgroups exist: extracellular signal-regulated kinase (ERK), c-Jun N-terminal of stress-activated protein kinases (JNK) and the p38 group of protein kinases. 12 The signalling cascades involving JNK and p38 are key mediators of stress signals and seem to be responsible mainly for protective responses, stress-dependent apoptosis and inflammatory responses. Conversely, the ERK pathway plays a major role in regulating cell proliferation and differentiation and provides a protective effect against apoptosis.
© 2005 Blackwell Publishing Asia Pty Ltd or p38 is involved in As2O3-induced apoptosis depends on the type of cell. c-Jun N-terminal kinase activation is mediates As2O3-induced apoptosis in acute promyelocytic leukaemia cells and in an acute myeloid leukaemia (M2)-derived cell line, but not in HepG2 cells. [13] [14] [15] Apoptosis induced by As2O3 in leukaemia U937 cells is dependent on activation of p38 but, in the NB4 cell line, p38 is a negative regulator of As2O3-induced apoptosis. 16, 17 The roles of JNK or p38 in As2O3-induced apoptosis in MCF-7 breast cancer cells remain to be clarified.
Combination of As2O3 with other drugs that activate additional apoptotic signals, or inhibit survival signals, may provide a rational molecular basis for novel chemotherapeutic strategies. A rational molecular target is the ERK MAPK. Extracellular signal-regulated kinase phosphorylates additional kinases and specific transcription factors, such as Elk-1 and c-Fos, are important in cell proliferation. However, the link between ERK activation and As2O3-induced cell death is not straightforward. [16] [17] [18] In the present study, we mainly tested the combined effects of As2O3 and MEK1/2 inhibitors on the induction of apoptosis of a breast cancer cell line. The human breast adenocarcinoma cell line MCF-7, an oestrogen receptor (ER)-positive breast cancer cell line, was examined as a cellular model for As2O3 treatment to mimic the early phase of breast cancer. The results showed that As2O3 increased MEK1/2 activity and combined treatment with As2O3 and MEK1/2 inhibition led to enhanced cell death in MCF-7 cells.
METHODS

Reagents and antibodies
A stock solution of As2O3 was prepared by dissolving As2O3 powder (Sigma, St Louis, MO, USA) in phosphate-buffered saline (PBS) to a concentration of 10 mmol/L. Primary antibodies, including polyclonal antiphospho-p42/44 MAPK (Thr202/Tyr204), polyclonal anti-p44/42 MAPK (ERK1/2), polyclonal anti-phospho-stress-activated protein kinase (SAPK)/ JNK (Thr183/Tyr185), polyclonal anti-SAPK/JNK, polyclonal antiphospho-p38 MAPK (Thr180/Tyr182), polyclonal anti-p38 MAPK, antirabbit IgG secondary antibody conjugated with horseradish peroxidase (HRP) and the MEK1/2 inhibitors U0126 and PD98059 were all purchased from Cell Signalling Technology (Beverly, MA, USA).
Cell lines and tissue culture
The MCF-7 cells were grown in RPMI 1640 supplemented with 10% heatinactivated fetal calf serum (FCS), 2 mmol/L L-glutamine, penicillin (100 U/mL) and streptomycin (100 mg/mL; Sigma), referred to as complete medium. Medium containing As2O3 was prepared by serial dilution of the 10 mmol/L As2O3 stock solution in RPMI 1640.
Cell viability assay
Cells were seeded in 96-well plates (5000 cells/well) and treated with indicated concentrations of As2O3 in the presence or absence of 10 mol/L U0126 or 20 mol/L PD98059 for 48 h. The 3-(4,5-dimethyl-2 thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay was used to assess cell viability: MTT, 20 L dissolved in PBS (5 mg MTT/mL PBS), was added to the cells. After 4 h incubation at 37 ЊC, culture medium containing MTT was removed and 100 L dimethylsulphoxide (DMSO) was added to solubilize the blue formazan formed by viable cells. Plates were read using an ELISA plate reader (EL808; Bio-Tek Instruments, Winooski, VT, USA) at 570 nm. Cell viability is expressed as a percentage ratio of exposed cells to control cells. 
Western blot analysis
Briefly, cells were lysed in buffer (0.5% NP-40, 10 mmol/L Tris-HCl, pH 7.2, 0.15 mol/L NaCl, 0.02% NaN3, 1 mmol/L phenylmethylsulphonyl fluoride), kept on ice for 30 min and centrifuged at 12 879 g for 10 min at 4 ЊC. Supernatants were collected, whereas nuclear debris were pelleted and discarded. Lysates (30 g) were run on 12.5% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) in Tris-glycine buffer. Gels were transferred to polyvinylidene difluoride (PVDF) using a semidry blotting apparatus in 25 mmol/L Tris, 192 mmol/L glycine and 20% methanol. After blocking in 2% non-fat dry milk for 1 h, membranes were 
Statistical analysis
Data are expressed as the meanϮSD. Two-way analysis of variance (ANOVA) was used to assess significant differences between treatment groups. P < 0.05 was considered statistically significant. (Fig. 2) . Further confirmation of As2O3-induced apoptosis was obtained using flow cytometry with annexin V-PI staining.
RESULTS
Effect of As2O3 on cell survival and apoptosis of MCF-7 cells
Effect of As2O3 on MAPK
To determine the involvement of MAPK in As2O3-induced cell death, western blots of MCF-7 cell extracts treated with As2O3 were performed using antibodies specific for phosphorylated forms. The blots showed a dose-dependent activation of ERK1/2 and p38, but not JNK1/2. (Fig. 3) 
Analysis of As2O3 and MEK inhibitors on the inhibition of cell growth breast cancer cells
In other systems, ERK generally plays a critical role in cell proliferation and growth; 22 thus, it was reasoned that ERK activation by As2O3 may enhance cell proliferation and compromise the efficacy of this drug. A logical approach to investigate this is to use pharmacologic blockers of MEK to inhibit As2O3-induced ERK activation and its downstream effects. To test this hypothesis, a combination of As2O3 and the MEK1/2 inhibitors U0126 or PD98059 was used to treat human breast carcinoma cell lines. The results showed that a combination of As2O3 and U0126 or PD98059 inhibited cell proliferation (Fig. 4a,b) . At low concentrations of 0.5 mol/L, As2O3, U0126 or PD98059 showed a modest, albeit not significant, enhancement of the inhibition of cell growth, whereas at higher concentrations of 2 and 5 mol/L, As2O3, U0126 or PD98059 were able to significantly inhibit cell proliferation compared with As2O3 alone in MCF-7 cells. These results are 
Arsenic trioxide and the MEK inhibitors U0126 or PD98059 enhance cell apoptosis
To assess whether apoptosis was involved in the enhanced inhibition of cell growth observed above, Hoechst 33258 staining or annexin V-PI staining was performed with As2O3, MEK inhibitor (U0126 or PD98059) or a combination of the two. Hoechst 33258 staining of MCF-7 cells revealed that the number of cells with condensed and fragmented fluorescent nuclei increased from 10% (treated with As2O3 alone) to 34% (treated with As2O3 and U0126) or 32% (treated with As2O3 and PD98059; Fig. 4a,b) . Similarly, As2O3 caused 12.7% apoptosis and U0126 caused 3.8% apoptosis, as measured by the number of annexin V-positive cells. When cells were treated with both As2O3 and U0126, there was a significant increase in the number of annexin V-positive cells to 38.6% (Fig. 4c) . These results indicate that MEK inhibition enhances As2O3-induced cell apoptosis.
Arsenic trioxide-induced cell death is independent of p38 pathways
To determine whether p38 kinase is involved in As2O3-induced apoptosis, 10 mol/L SB203580, a selective inhibitor of p38 kinase, was added to MCF-7 cells treated with As2O3. Hoechst 33258 staining of MCF-7 cells was used to evaluate apoptosis. The results showed that SB203580 did not block the apoptosis induced by As2O3. The addition of SB203580 to MCF-7 cells treated with As2O3 increased the apoptotic fraction, but this was not statistically significant (Fig. 6 ).
DISCUSSION
Increasingly, more studies have revealed the effectiveness of As2O3 in acting against solid tumours since its pilot treatment of APL patients. [1] [2] [3] [4] In view of the promising effectiveness of As2O3 as a chemotherapeutic drug, the potential application of As2O3 in breast cancer treatment was explored in the present study. The cytotoxicity of As2O3 against human breast cancer MCF-7 cells was assessed using several parameters. The results of the MTT assay showed a dose-and time-dependent inhibition of the growth of MCF-7 cells by As2O3. The antitumour effects of As2O3 against APL cell lines and other solid human tumours are as a result of the induction of apoptosis. [19] [20] [21] In the present study, As2O3 was also found to induce apoptosis in MCF-7 cells. This was supported by evidence that MCF-7 cells treated with 5 mol/L As2O3 for 3 days showed condensed and fragmented fluorescent nuclei following Hoechst 33258 staining. To further confirm the induction of apoptosis by As2O3, we examined the externalization of phosphatidylserine (PS) by flow cytometry with annexin V-PI staining. The data indicated that PS externalization and necrotic cells were evident in MCF-7 cells treated with As2O3. These results suggest that As2O3-induced apoptosis contributes to the growth inhibition of MCF-7 cells.
The As2O3-induced apoptosis occurs via a variety of mechanisms that include caspases, reactive oxygen species, p53, Bcl-2, protein kinase C and MAPK. 13, 14, [22] [23] [24] [25] [26] [27] [28] However, which mechanism is actually critical for As2O3-induced apoptosis, especially in solid cancers, has yet to be determined. In the present study, we focused mainly on the role of MAPK in As2O3-induced apoptosis of MCF-7 cells. The MAPK signalling cascades regulate a variety of cellular activities, including cell growth, differentiation, survival and death. In mammals, the MAPK family is divided into three major groups, namely ERK, JNK and p38, based on their degree of homology, biological activities and phosphorylation motifs.
c-Jun N-terminal kinase and p38 belong to the SAPK family and have been investigated in As2O3-induced apoptosis. It has been reported that As2O3 induced JNK activation and apoptosis in APL and that a JNK inhibitor significantly protected against As2O3-induced apoptosis. 13 In the the acute myeloid leukaemia (M2)-derived cell line NKM-1, As2O3 induced sustained activation of JNK and apoptosis and addition of a JNK inhibitor reduced the percentage of apoptotic cells after As2O3 treatment.
14 Arsenic trioxide is able to induce apoptotic activity in K562 cells and its apoptotic mechanism may be associated with the activation of p38. 29 Arsenic trioxide leads to the activation of p38, which plays a role in inducing apoptosis by As2O3 in human leukaemia U937 cells. 16 In HepG2 cells, activation of p38 by As2O3 may not be the Pharmacological inhibition of p38 potentiates arsenic-dependent apoptosis and suppression of growth of leukaemia cell lines, suggesting that this signalling cascade negatively regulates the induction of antileukaemic responses by As2O3. 17 Arsenic trioxide causes the dose-dependent activation of p38, JNK and caspase 3. Treatment with a p38 inhibitor and overexpression of dominantnegative JNK did not prevent As2O3-induced cell death. 10 These diverse observations regarding the nature of the signalling pathways in As2O3-induced apoptosis represent the unusual characteristics of the mechanism of apoptosis induced by As2O3 in different cellular systems. In the present study, p38 was activated in As2O3-induced apoptosis, but the inhibition of p38 did not protect MCF-7 cells from As2O3-induced apoptosis. c-Jun N-terminal kinase 1/2 was not activated, even at a concentration of 10 mol/L As2O3. These results indicate that p38 and JNK are not involved in As2O3-induced apoptosis in the MCF-7 cell line.
In mammalian cells, Raf/MEK/ERK was the first MAPK cascade to be identified and is the most extensively studied. Activation of Raf/MEK/ERK plays a pivotal role in the physiological regulation of many cellular processes, such as growth, proliferation, differentiation, survival, motility and angiogenesis. 12, 30, 31 Although exceptions occur, the bulk of the evidence indicates that constitutive activation of the MEK/ERK signalling module increases the apoptotic threshold of cancer cells, consistent with its ability to regulate the expression and function of multiple anti-apoptotic players through transcriptional and nontranscriptional mechanisms. [32] [33] [34] The MEK/ERK MAPK module has recently emerged as a potential target for anticancer therapies. Indeed, one of the most intriguing features of MEK inhibitors is their ability to lower the apoptotic threshold of leukaemic cells, thereby sensitizing them to the pro-apoptotic action of other biological agents, ionizing radiation and biological agents that modulate apoptosis. 35 Additive or synergistic antiproliferative and/ or pro-apoptotic effects have also been reported recently in lymphoid and myeloid cells when inhibitors of the MEK/ERK MAPK module are combined with non-conventional cytostatics/ cytotoxics, such as interferon-␣. 36 In present study, treatment of MCF-7 cells with As2O3 resulted in the activation of ERK, so we questioned whether ERK activation by As2O3 may enhance cell proliferation and compromise the efficacy of this drug. To answer this question, a combination of As2O3 and the potent MEK1/2 inhibitors U0126 or PD98059 was used to treat the human breast carcinoma line. The results confirm that a combination of As2O3 with MEK inhibition enhances cell growth inhibition and apoptosis. The potential use of low-dose chemotherapy is important, because lower doses are more attainable during cancer therapy and are likely to cause less toxicity in patients. We performed a dose-response analysis to assess the minimal concentration of As2O3 that, when combined with U0126, causes enhanced cell death. Low doses of As2O3, starting in the 2 mol/L range, combined with U0126 cause significantly enhanced cell growth inhibition of MCF-7 breast carcinoma cells. Annexin V-PI and Hoechst 33258 staining confirmed that the cell death observed above represented apoptosis. More recently, As2O3 has been reported to stimulate ERK activation and subsequent ERKmediated BAD phosphorylation on Ser112, thereby inhibiting its pro-apoptotic function, in APL cells. 20 The inhibition of ERK1/2 and Bad phosphorylation by MEK1 inhibitors enhanced apoptosis in As2O3-treated cells. 20 It remain to be clarified whether there was a similar mechanism operating in the present study.
Based on a molecular approach, the present study mainly documents that treatment with As2O3, combined with the inhibition of MEK1/2, led to enhanced apoptosis of a breast carcinoma cell line. The combination therapy of As2O3 and MEK inhibitor may allow the use of lower drug doses, likely leading to lower toxicity and enhanced breast tumour killing in vivo. There are broad implications for these findings in the potential clinical use of As2O3 and MEK inhibitors by improving the response rate and expanding the usefulness of As2O3 in the treatment of resistant tumours, which affect a large percentage of cancer patients.
